Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Novo Nordisk A/SNYSE: NVO

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures dips below year-ago levels

Q2 FY2026 capital expenditures of DKK 12.8B (cash outflow) fell 21.3% year over year, behind the +40.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 6.3% from the prior quarter. Over 3 fiscal years it compounded at +82.8% a year.

Context

  • Capital expenditures amounted to 29.2% of revenue in FY2025, up 11.5 pp from a year earlier.
  • Capital expenditures grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -21.3% toward the trailing-twelve-month pace of +40.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-DKK 12.8B+6.3% QoQ
Last fiscal yearDec 2025
-DKK 90.11B+75.6% YoY
LTMJun 2026
-DKK 84.09B+40.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.3%——
1 year+75.6%——
3-year CAGR+82.8%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

DKK · from the cash flow

Latest · FY2025
(90.11B) DKK
Year-over-year change
-75.6%

Capital Expenditures vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +40.3% is the 2nd highest of 9, against a peer median of -4.9%.
  • Capital expenditures amounts to 25.5% of revenue for NVO, versus a peer median of 5.6%.
NVO Competitors
Capital Expenditures for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 84.09B DKK+40.3%+82.8%25.5%
LLYEli Lilly and CompanyLTM Jun 2026$8.03B USD-26.9%+38.0%10.1%
JNJJohnson & JohnsonLTM Sep 2026$5.57B USD+8.6%+6.4%5.6%
AZNAstraZeneca PLCLTM Sep 2026$4.01B USD-28.0%+31.9%6.5%
MRKMerck & Co., Inc.LTM Jun 2026$3.9B USD+2.4%-2.1%5.9%
SNYSanofiLTM Jun 2026€2.52B EUR—-1.8%5.2%
PFEPfizer Inc.LTM Jun 2026$2.42B USD-12.1%-6.7%3.8%
AMGNAmgen Inc.LTM Jun 2026$2.3B USD+63.6%+25.7%6.0%
GSKGSK plcLTM Jun 2026£1.76B GBP-42.4%-2.2%5.3%
ABBVAbbVie Inc.LTM Jun 2026$1.3B USD+24.2%+20.4%2.0%
Peer median (excluding NVO) —-4.9%+6.4%5.6%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.